Inovio Pharmaceuticals. has filed a patent for a method to prepare an electroporation device for delivering treatment. The method involves charging a supercapacitor unit with a charge current from a battery, adjusting the current based on input parameters, all controlled by a machine-readable control unit. GlobalData’s report on Inovio Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Inovio Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Inovio Pharmaceuticals, Personalized cancer vaccines was a key innovation area identified from patents. Inovio Pharmaceuticals's grant share as of January 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.

Method for preparing electroporation device for treatment using charge current

Source: United States Patent and Trademark Office (USPTO). Credit: Inovio Pharmaceuticals Inc

A patent application (Publication Number: US20240017061A1) describes a method for preparing an electroporation device for delivering an electroporation treatment. The method involves delivering a charge current from at least one battery through a charge circuit to a supercapacitor unit, charging the supercapacitor unit while measuring input parameters of the charge current, and transitioning the charge current between different charge states based on the measured parameters. The process is automatically controlled by a control unit executing machine-readable instructions. The method includes adjusting the magnitude of the charge current and transitioning between primary charge states to optimize the charging process efficiently.

Furthermore, the patent application details the specific input parameters measured during the charging process, such as battery voltage, boosted voltages, and charging duration. The method also includes transitioning the charge current to a top-off charge state after the supercapacitor unit reaches a full charge level, indicating that the device is treatment ready. The patent application also describes the communication of indication signals to the user, including optical signals through LED displays and audible signals through a speaker. Additionally, the application discusses a power supply unit for the electroporation device, which includes a battery unit, energy storage unit, integrated circuit, and charge circuit. The power supply unit is designed to work with different types of batteries, measure input parameters, and adjust the charge current accordingly to optimize the charging process for the supercapacitor unit within the electroporation device.

To know more about GlobalData’s detailed insights on Inovio Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies